Haemonetics (HAE) Share-based Compensation (2009 - 2026)

Haemonetics' Share-based Compensation history runs 18 years deep, the most recent figure standing at $46000.0 for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 100.37% year-over-year to $46000.0 in Q1 2026; TTM through Mar 2026 was $5.0 million, a 51.18% decrease from a year earlier, with the FY2026 full-year figure at $5.0 million, down 51.18% from the prior year.
• Share-based Compensation retreated to $46000.0 in Q1 2026 per HAE's latest filing, from $160000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $11.0 million in Q4 2022 and bottomed at -$19.3 million in Q2 2022.
• The 5-year median for Share-based Compensation is $2.4 million (2024), against an average of $520125.0.
• Across the five-year window, Share-based Compensation tumbled 370.91% in 2022 and soared 19002.33% in 2024, its largest moves.
• Year by year, Share-based Compensation stood at $7.5 million in 2022, then tumbled by 99.43% to $43000.0 in 2023, then surged by 19002.33% to $8.2 million in 2024, then sank by 98.05% to $160000.0 in 2025, then slumped by 71.25% to $46000.0 in 2026.
• Per Business Quant, the three latest HAE Share-based Compensation figures stand at $46000.0 (Q1 2026), $160000.0 (Q4 2025), and -$4.5 million (Q3 2025).